Published in Medical Letter on the CDC and FDA, July 16th, 2006
The patent's claims expand the coverage for the company's transcutaneous immunization (TCI) technology, according to the company a unique method of vaccine delivery with benefits including needle-free administration and the ability to deliver types of vaccines that are not viable by an intramuscular route. Iomai's TCI technology uses a patch applied to the skin like a bandage and worn for several hours to deliver vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA